Avenge Bio is a biotech company based in Natick, MA, founded by a team of experienced executives in the field. They are focused on developing transformative therapeutics to potentially eradicate solid tumors that are difficult to treat. Avenge Bio utilizes their proprietary LOCOcyteTM platform, which enables precision delivery of immunomodulatory molecules for a controlled period of time, generating robust anti-tumor immune responses without the toxicities associated with traditional immunotherapies.
The company has a broad pipeline of therapeutics targeting a wide range of intractable solid tumors. They are currently conducting a Phase 1/2 clinical trial (NCT05538624) to evaluate the safety and efficacy of their product AVB-001 in patients with serous adenocarcinoma of the ovary. Avenge Bio is committed to advancing the development of their products and may revise their expanded access policy in the future.
Generated from the website